{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:36:05Z","timestamp":1787060165027,"version":"build-2736575974"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH 1 K23 GM110516"],"award-info":[{"award-number":["NIH 1 K23 GM110516"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH CTSI UL1 TR001082"],"award-info":[{"award-number":["NIH CTSI UL1 TR001082"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001459","name":"American Medical Association Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001459","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10557-017-6733-2","type":"journal-article","created":{"date-parts":[[2017,7,23]],"date-time":"2017-07-23T23:19:48Z","timestamp":1500851988000},"page":"471-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-3302","authenticated-orcid":false,"given":"Hania K.","family":"Flaten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"6733_CR1","volume-title":"Hypertension among adults in the US: National Health and Nutrition Examination Survey, 2011\u20132012. NCHS data brief, no. 133","author":"T Nwankwo","year":"2013","unstructured":"Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the US: National Health and Nutrition Examination Survey, 2011\u20132012. NCHS data brief, no. 133. National Center for Health Statistics, Centers for Disease Control: Hyattsville; 2013."},{"issue":"Suppl 1","key":"6733_CR2","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3109\/07853890.2011.653399","volume":"44","author":"JA Johnson","year":"2012","unstructured":"Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med. 2012;44(Suppl 1):S17\u201322.","journal-title":"Ann Med"},{"key":"6733_CR3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archinte.161.6.880","volume":"161","author":"JS Cohen","year":"2001","unstructured":"Cohen JS. Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians\u2019 Desk Reference. Arch Intern Med. 2001;161:880\u20135.","journal-title":"Arch Intern Med"},{"key":"6733_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"6733_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1471-2296-14-192","volume":"14","author":"A Filippi","year":"2013","unstructured":"Filippi A, Sangiorgi D, Buda S, Degli Esposti L, Nati G, Paolini I, et al. How many hypertensive patients can be controlled in \u201creal life\u201d: an improvement strategy in primary care. BMC Fam Pract. 2013;14:192.","journal-title":"BMC Fam Pract"},{"key":"6733_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/tmj.2012.0036","volume":"19","author":"MV Santos","year":"2013","unstructured":"Santos MV, Oliveira DC, Novaes MA. A telehealth strategy for increasing adherence in the treatment of hypertension in primary care. Telemed J E Health. 2013;19:241\u20137.","journal-title":"Telemed J E Health"},{"key":"6733_CR7","first-page":"295","volume":"12","author":"S Erdine","year":"2012","unstructured":"Erdine S. How do compliance, convenience, and tolerability affect blood pressure goal rates? Am J Cardiovasc Drugs. 2012;12:295\u2013302.","journal-title":"Am J Cardiovasc Drugs"},{"key":"6733_CR8","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1111\/j.1365-2702.2012.04321.x","volume":"22","author":"F Alhalaiqa","year":"2013","unstructured":"Alhalaiqa F, Deane KH, Gray R. Hypertensive patients\u2019 experience with adherence therapy for enhancing medication compliance: a qualitative exploration. J Clin Nurs. 2013;22:2039\u201352.","journal-title":"J Clin Nurs"},{"key":"6733_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-014-0239-7","volume":"38","author":"HM Abraham","year":"2015","unstructured":"Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38:33\u201354.","journal-title":"Drug Saf"},{"key":"6733_CR10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/j.1875-9114.1998.tb03157.x","volume":"18","author":"CM White","year":"1998","unstructured":"White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998;18:588\u201399.","journal-title":"Pharmacotherapy"},{"key":"6733_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1081\/CEH-200032144","volume":"26","author":"S Erdine","year":"2004","unstructured":"Erdine S, Aran SN. Current status of hypertension control around the world. Clin Exp Hypertens. 2004;26:731\u20138.","journal-title":"Clin Exp Hypertens"},{"key":"6733_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/psp4.12017","volume":"4","author":"DM Rotroff","year":"2015","unstructured":"Rotroff DM, Shahin MH, Gurley SB, Zhu H, Motsinger-Reif A, Meisner M, et al. Pharmacometabolomic assessments of atenolol and hydrochlorothiazide treatment reveal novel drug response phenotypes. CPT Pharmacometrics Syst Pharmacol. 2015;4:669\u201379.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"6733_CR13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/01.HYP.35.6.1291","volume":"35","author":"P Sharma","year":"2000","unstructured":"Sharma P, Fatibene J, Ferraro F, Jia H, Monteith S, Brown C, et al. A genome-wide search for susceptibility loci to human essential hypertension. Hypertension. 2000;35:1291\u20136.","journal-title":"Hypertension"},{"key":"6733_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.apcsb.2015.09.003","volume":"102","author":"N Koen","year":"2016","unstructured":"Koen N, Du Preez I, Loots DT. Metabolomics and personalized medicine. Adv Protein Chem Struct Biol. 2016;102:53\u201378.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"6733_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/wsbm.1302","volume":"7","author":"RM Turner","year":"2015","unstructured":"Turner RM, Park BK, Pirmohamed M. Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip rev Syst Biol med. 2015;7:221\u201341.","journal-title":"Wiley Interdiscip rev Syst Biol med"},{"key":"6733_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1248\/yakushi.14-00230-4","volume":"135","author":"N Kaniwa","year":"2015","unstructured":"Kaniwa N. Utilization of genomic biomarkers for post-marketing safety of drugs. Yakugaku Zasshi. 2015;135:671\u20139.","journal-title":"Yakugaku Zasshi"},{"key":"6733_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793\u20135.","journal-title":"N Engl J Med"},{"key":"6733_CR18","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJM197805042981803","volume":"298","author":"H Gavras","year":"1978","unstructured":"Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978;298:991\u20135.","journal-title":"N Engl J Med"},{"key":"6733_CR19","unstructured":"Medicines use and spending shifts. In: Aitken M editor. A review of the use of medicines in the US in 2014. Parsippany: IMS Institute for Healthcare Informatics. 2015:41. https:\/\/www.imshealth.com\/files\/web\/IMSH%20Institute\/Reports\/Medicines_Use_and_Spending_Shifts\/Medicine-Spending-and-Growth_1995-2014.pdf .\u00a0Accessed 9 Sept 2016.\u00a0"},{"key":"6733_CR20","unstructured":"IMS Institute for Healthcare Informatics.\u00a0The use of medicines in the United States: review of 2011. 2012. www.imshealth.com\/ims\/Global\/Content\/Insights\/IMS%20Institute%20for%20Healthcare%20Informatics\/IHII_Medicines_in_U.S_Report_2011.pdf .\u00a0Accessed 9 Sept 2016."},{"key":"6733_CR21","unstructured":"Jackson EK. Renin and Angiotensin. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman\u2018s the pharmacological basis of therapeutics 11th ed.\u00a0New York: McGraw Hill; 2006. pp. 789-821."},{"key":"6733_CR22","unstructured":"Zestril (lisinopril) [package insert]. Wilmington DE: AstraZeneca Pharmaceuticals LP; 2008."},{"key":"6733_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1755-5922.2008.00066.x","volume":"27","author":"G Alici","year":"2009","unstructured":"Alici G, Aliyev F, Bellur G, Okcun B, T\u00fcrko\u011flu C, Karpuz H. Effect of seven different modalities of antihypertensive therapy on pulse pressure in patients with newly diagnosed stage I hypertension. Cardiovasc Ther. 2009;27:4\u20139.","journal-title":"Cardiovasc Ther"},{"key":"6733_CR24","unstructured":"Vasotec (enalapril) [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2011."},{"key":"6733_CR25","doi-asserted-by":"crossref","unstructured":"Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2008:CD003823.","DOI":"10.1002\/14651858.CD003823.pub2"},{"key":"6733_CR26","unstructured":"Altace (ramipril)[package insert]. New York, NY: Pfizer Laboratories Div Pfizer Inc; 2011."},{"key":"6733_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jch.12603","volume":"17","author":"RE Schmieder","year":"2015","unstructured":"Schmieder RE, Potthoff SA, Bramlage P, Baumgart P, Mahfoud F, Buhck H, et al. Patients with newly diagnosed hypertension treated with the renin angiotensin receptor blocker azilsartan medoxomil vs angiotensin-converting enzyme inhibitors: the prospective EARLY Registry. J Clin Hypertens (Greenwich). 2015;17:947\u201353.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"6733_CR28","unstructured":"Quinapril [package insert]. Columbus, OH: American Health Packaging; 2015."},{"key":"6733_CR29","unstructured":"Benazepril Hydrochloride [package insert]. St. Louis, MO: KV Pharmaceutical Co; 2007."},{"key":"6733_CR30","unstructured":"Diovan (Valsartan) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2015."},{"key":"6733_CR31","unstructured":"Losartan potassium [package insert]. Village Panelav, P.O. Tajpura, Near Baska, Taluka-Halol, Panchmahal, Gujarat, India: Alembic Pharmaceuticals Limited; 2011."},{"key":"6733_CR32","unstructured":"Benicar (olmesartan medoxomil) [package insert]. Parsippany, NJ: Daiichi Sankyo; 2009."},{"key":"6733_CR33","unstructured":"Irbesartan [package insert]. Daman (U.T) India: Macleods Pharmaceutical Limited; 2014."},{"key":"6733_CR34","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1161\/01.HYP.31.6.1311","volume":"31","author":"RA Reeves","year":"1998","unstructured":"Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension. 1998;31:1311\u20136.","journal-title":"Hypertension"},{"key":"6733_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","volume":"355","author":"M Burnier","year":"2000","unstructured":"Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637\u201345.","journal-title":"Lancet"},{"key":"6733_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0014-2999(98)00965-0","volume":"367","author":"F Fierens","year":"1999","unstructured":"Fierens F, Vanderheyden PM, De Backer JP, Vauquelin G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. Eur J Pharmacol. 1999;367:413\u201322.","journal-title":"Eur J Pharmacol"},{"key":"6733_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0014-2999(99)00205-8","volume":"372","author":"FL Fierens","year":"1999","unstructured":"Fierens FL, Vanderheyden PM, De Backer JP, Vauquelin G. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol. 1999;372:199\u2013206.","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 1","key":"6733_CR38","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","volume":"14","author":"ZH Israili","year":"2000","unstructured":"Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(Suppl 1):S73\u201386.","journal-title":"J Hum Hypertens"},{"key":"6733_CR39","doi-asserted-by":"crossref","unstructured":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981\u201397.","DOI":"10.1001\/jama.288.23.2981"},{"key":"6733_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0895-7061(00)01266-8","volume":"14","author":"AI Anderson","year":"2001","unstructured":"Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens. 2001;14:241\u20137.","journal-title":"Am J Hypertens"},{"key":"6733_CR41","unstructured":"Information for healthcare professionals: Angiotensin-Converting Enzyme Inhibitor (ACE inhibitor) Drugs and Pregnancy. U.S. Food and Drug Administration; 2013."},{"key":"6733_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/08998280.2003.11927893","volume":"16","author":"A Barreras","year":"2003","unstructured":"Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent). 2003;16:123\u20136.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"6733_CR43","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/1470320314538878","volume":"16","author":"F Heidari","year":"2015","unstructured":"Heidari F, Vasudevan R, Mohd Ali SZ, Ismail P, Etemad A, Pishva SR, et al. Association of insertion\/deletion polymorphism of angiotensin-converting enzyme gene among Malay male hypertensive subjects in response to ACE inhibitors. J Renin-Angiotensin-Aldosterone Syst. 2015;16:872\u20139.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"6733_CR44","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI114844","volume":"86","author":"B Rigat","year":"1990","unstructured":"Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343\u20136.","journal-title":"J Clin Invest"},{"key":"6733_CR45","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/01.CIR.92.6.1387","volume":"92","author":"AH Danser","year":"1995","unstructured":"Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion\/insertion polymorphism. Circulation. 1995;92:1387\u20138.","journal-title":"Circulation"},{"key":"6733_CR46","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1097\/00004872-200110000-00012","volume":"19","author":"L Kurland","year":"2001","unstructured":"Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens. 2001;19:1783\u20137.","journal-title":"J Hypertens"},{"key":"6733_CR47","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2217\/pgs.12.206","volume":"14","author":"SH Mahmoudpour","year":"2013","unstructured":"Mahmoudpour SH, Leusink M, van der Putten L, Terreehorst I, Asselbergs FW, de Boer A, et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics. 2013;14:249\u201360.","journal-title":"Pharmacogenomics"},{"key":"6733_CR48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0895-7061(02)02256-2","volume":"15","author":"L Kurland","year":"2002","unstructured":"Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, et al. Aldosterone synthase (CYP11B2) -344 C\/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens. 2002;15:389\u201393.","journal-title":"Am J Hypertens"},{"key":"6733_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0014-2999(02)01766-1","volume":"445","author":"JR Ortlepp","year":"2002","unstructured":"Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol. 2002;445:151\u20132.","journal-title":"Eur J Pharmacol"},{"key":"6733_CR50","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1097\/00004872-200210000-00030","volume":"20","author":"P Hallberg","year":"2002","unstructured":"Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens. 2002;20:2089\u201393.","journal-title":"J Hypertens"},{"key":"6733_CR51","first-page":"1602","volume":"13","author":"AD Hingorani","year":"1995","unstructured":"Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens. 1995;13:1602\u20139.","journal-title":"J Hypertens"},{"key":"6733_CR52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00004872-199602000-00016","volume":"14","author":"C Dudley","year":"1996","unstructured":"Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens. 1996;14:259\u201362.","journal-title":"J Hypertens"},{"key":"6733_CR53","doi-asserted-by":"publisher","first-page":"e0153163","DOI":"10.1371\/journal.pone.0153163","volume":"11","author":"E Altmaier","year":"2016","unstructured":"Altmaier E, Menni C, Heier M, Meisinger C, Thorand B, Quell J, et al. The pharmacogenetic footprint of ACE inhibition: a population-based metabolomics study. PLoS One. 2016;11:e0153163.","journal-title":"PLoS One"},{"key":"6733_CR54","doi-asserted-by":"publisher","first-page":"17253","DOI":"10.1038\/srep17253","volume":"5","author":"JQ Luo","year":"2015","unstructured":"Luo JQ, He FZ, Wang ZM, Sun NL, Wang LY, Tang GF, et al. SLCO1B1 variants and angiotensin converting enzyme inhibitor (enalapril)-induced cough: a pharmacogenetic study. Sci rep. 2015;5:17253.","journal-title":"Sci rep"},{"key":"6733_CR55","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/FPC.0b013e328348c6db","volume":"21","author":"S Mas","year":"2011","unstructured":"Mas S, Gass\u00f2 P, Alvarez S, Ortiz J, Sotoca JM, Francino A, et al. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenet Genomics. 2011;21:531\u20138.","journal-title":"Pharmacogenet Genomics"},{"key":"6733_CR56","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/tpj.2009.70","volume":"10","author":"CM Chung","year":"2010","unstructured":"Chung CM, Wang RY, Chen JW, Fann CS, Leu HB, Ho HY, et al. A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor. Pharmacogenomics J. 2010;10:537\u201344.","journal-title":"Pharmacogenomics J"},{"key":"6733_CR57","doi-asserted-by":"crossref","unstructured":"Mosley JD, Shaffer CM, Van Driest SL, Weeke PE, Wells QS, Karnes JH, et al. A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough. Pharmacogenomics J. 2015.","DOI":"10.1038\/tpj.2015.51"},{"key":"6733_CR58","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/FPC.0b013e328363c137","volume":"23","author":"G Pare","year":"2013","unstructured":"Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013;23:470\u20138.","journal-title":"Pharmacogenet Genomics"},{"key":"6733_CR59","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/FPC.0b013e32833d3acb","volume":"20","author":"AV Woodard-Grice","year":"2010","unstructured":"Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2010;20:532\u20136.","journal-title":"Pharmacogenet Genomics"},{"key":"6733_CR60","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.2337\/dc09-0348","volume":"32","author":"T Konoshita","year":"2009","unstructured":"Konoshita T, Kato N, Fuchs S, Mizuno S, Aoyama C, Motomura M, et al. Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers. Diabetes Care. 2009;32:1485\u201390.","journal-title":"Diabetes Care"},{"key":"6733_CR61","doi-asserted-by":"crossref","unstructured":"Baruah S, Chaliha MS, Borah PK, Rajkakati R, Borua PK, Mahanta J. Insertion\/insertion genotype of angiotensin I-converting-enzyme gene predicts risk of myocardial infarction in North East India. Biochem Genet 2015.","DOI":"10.1007\/s10528-015-9706-9"},{"key":"6733_CR62","doi-asserted-by":"publisher","first-page":"8068","DOI":"10.4238\/2015.July.17.15","volume":"14","author":"W Zhao","year":"2015","unstructured":"Zhao W, Ma ST, Cui LQ. Meta-analysis of angiotensin-converting enzyme insertion\/deletion polymorphism and myocardial infarction in Han Chinese. Genet Mol res. 2015;14:8068\u201376.","journal-title":"Genet Mol res"},{"key":"6733_CR63","first-page":"557","volume":"73","author":"A Amrani","year":"2015","unstructured":"Amrani A, Baba Hamed MB, Mesli TF. Association study between some renin-angiotensin system gene variants and essential hypertension in a sample of Algerian population: case control study. Ann Biol Clin (Paris). 2015;73:557\u201363.","journal-title":"Ann Biol Clin (Paris)"},{"key":"6733_CR64","first-page":"979631","volume":"2015","author":"D Tchelougou","year":"2015","unstructured":"Tchelougou D, Kologo JK, Karou SD, Yam\u00e9ogo VN, Bisseye C, Djigma FW, et al. Renin-angiotensin system genes polymorphisms and essential hypertension in Burkina Faso. West Africa Int J Hypertens. 2015;2015:979631.","journal-title":"West Africa Int J Hypertens"},{"key":"6733_CR65","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1161\/01.CIR.91.12.2933","volume":"91","author":"ML Lachuri\u00e9","year":"1995","unstructured":"Lachuri\u00e9 ML, Azizi M, Guyene TT, Alhenc-Gelas F, M\u00e9nard J. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation. 1995;91:2933\u201342.","journal-title":"Circulation"},{"key":"6733_CR66","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/00004872-199917121-00014","volume":"17","author":"AH Danser","year":"1999","unstructured":"Danser AH, Deinum J, Osterop AP, Admiraal PJ, Schalekamp MA. Angiotensin I to angiotensin II conversion in the human forearm and leg. Effect of the angiotensin converting enzyme gene insertion\/deletion polymorphism. J Hypertens. 1999;17:1867\u201372.","journal-title":"J Hypertens"},{"key":"6733_CR67","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1161\/01.HYP.25.6.1266","volume":"25","author":"S Ueda","year":"1995","unstructured":"Ueda S, Elliott HL, Morton JJ, Connell JM. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension. 1995;25:1266\u20139.","journal-title":"Hypertension"},{"key":"6733_CR68","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/oxfordjournals.eurheartj.a014947","volume":"17","author":"H Buikema","year":"1996","unstructured":"Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J. 1996;17:787\u201394.","journal-title":"Eur Heart J"},{"key":"6733_CR69","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1097\/00004872-200212000-00018","volume":"20","author":"S Fuchs","year":"2002","unstructured":"Fuchs S, Philippe J, Germain S, Mathieu F, Jeunemaitre X, Corvol P, et al. Functionality of two new polymorphisms in the human renin gene enhancer region. J Hypertens. 2002;20:2391\u20138.","journal-title":"J Hypertens"},{"key":"6733_CR70","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1042\/cs0640273","volume":"64","author":"TW Meade","year":"1983","unstructured":"Meade TW, Imeson JD, Gordon D, Peart WS. The epidemiology of plasma renin. Clin Sci (Lond). 1983;64:273\u201380.","journal-title":"Clin Sci (Lond)"},{"key":"6733_CR71","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2165\/00002512-199405050-00007","volume":"5","author":"J Belmin","year":"1994","unstructured":"Belmin J, L\u00e9vy BI, Michel JB. Changes in the renin-angiotensin-aldosterone axis in later life. Drugs Aging. 1994;5:391\u2013400.","journal-title":"Drugs Aging"},{"key":"6733_CR72","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1210\/jcem-62-2-384","volume":"62","author":"K Tsunoda","year":"1986","unstructured":"Tsunoda K, Abe K, Goto T, Yasujima M, Sato M, Omata K, et al. Effect of age on the renin-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasma. J Clin Endocrinol Metab. 1986;62:384\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"6733_CR73","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/hrt.2006.107706","volume":"93","author":"MJ Brown","year":"2007","unstructured":"Brown MJ. Renin: friend or foe? Heart. 2007;93:1026\u201333.","journal-title":"Heart"},{"key":"6733_CR74","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0090-9556(25)06533-X","volume":"23","author":"CH Yun","year":"1995","unstructured":"Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos. 1995;23:285\u20139.","journal-title":"Drug Metab Dispos"},{"key":"6733_CR75","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0090-9556(25)06520-1","volume":"23","author":"RA Stearns","year":"1995","unstructured":"Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos. 1995;23:207\u201315.","journal-title":"Drug Metab Dispos"},{"key":"6733_CR76","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2165\/00129784-200707050-00004","volume":"7","author":"DH Smith","year":"2007","unstructured":"Smith DH. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. Am J Cardiovasc Drugs. 2007;7:347\u201356.","journal-title":"Am J Cardiovasc Drugs"},{"key":"6733_CR77","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.jhh.1000788","volume":"13","author":"JL Pool","year":"1999","unstructured":"Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999;13:275\u201381.","journal-title":"J Hum Hypertens"},{"key":"6733_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00008571-200301000-00003","volume":"13","author":"U Liljedahl","year":"2003","unstructured":"Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics. 2003;13:7\u201317.","journal-title":"Pharmacogenetics"},{"key":"6733_CR79","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1172\/JCI117803","volume":"95","author":"LJ Bloem","year":"1995","unstructured":"Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest. 1995;95:948\u201353.","journal-title":"J Clin Invest"},{"key":"6733_CR80","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1124\/jpet.106.103390","volume":"318","author":"L Liu","year":"2006","unstructured":"Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, et al. Vectorial transport of enalapril by Oatp1a1\/Mrp2 and OATP1B1 and OATP1B3\/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006;318:395\u2013402.","journal-title":"J Pharmacol Exp Ther"},{"key":"6733_CR81","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.clpt.2006.01.011","volume":"79","author":"K Maeda","year":"2006","unstructured":"Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther. 2006;79:427\u201339.","journal-title":"Clin Pharmacol Ther"},{"key":"6733_CR82","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10038-008-0324-9","volume":"53","author":"S Suwannakul","year":"2008","unstructured":"Suwannakul S, Ieiri I, Kimura M, Kawabata K, Kusuhara H, Hirota T, et al. Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J hum Genet. 2008;53:899\u2013904.","journal-title":"J hum Genet"},{"key":"6733_CR83","doi-asserted-by":"publisher","first-page":"e56179","DOI":"10.1371\/journal.pone.0056179","volume":"8","author":"BE Himes","year":"2013","unstructured":"Himes BE, Sheppard K, Berndt A, Leme AS, Myers RA, Gignoux CR, et al. Integration of mouse and human genome-wide association data identifies KCNIP4 as an asthma gene. PLoS One. 2013;8:e56179.","journal-title":"PLoS One"},{"key":"6733_CR84","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","volume":"60","author":"NJ Brown","year":"1996","unstructured":"Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8\u201313.","journal-title":"Clin Pharmacol Ther"},{"key":"6733_CR85","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","volume":"165","author":"JB Kostis","year":"2005","unstructured":"Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637\u201342.","journal-title":"Arch Intern Med"},{"key":"6733_CR86","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","volume":"51","author":"DR Miller","year":"2008","unstructured":"Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:1624\u201330.","journal-title":"Hypertension"},{"key":"6733_CR87","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1081-1206(10)60860-5","volume":"98","author":"B Malde","year":"2007","unstructured":"Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol. 2007;98:57\u201363.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"6733_CR88","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10654-014-9910-7","volume":"29","author":"E Altmaier","year":"2014","unstructured":"Altmaier E, Fobo G, Heier M, Thorand B, Meisinger C, R\u00f6misch-Margl W, et al. Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism. Eur J Epidemiol. 2014;29:325\u201336.","journal-title":"Eur J Epidemiol"},{"key":"6733_CR89","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1161\/01.RES.0000258855.60637.58","volume":"100","author":"I Bogdarina","year":"2007","unstructured":"Bogdarina I, Welham S, King PJ, Burns SP, Clark AJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res. 2007;100:520\u20136.","journal-title":"Circ Res"},{"key":"6733_CR90","doi-asserted-by":"publisher","first-page":"e106138","DOI":"10.1371\/journal.pone.0106138","volume":"9","author":"M Rangel","year":"2014","unstructured":"Rangel M, dos Santos JC, Ortiz PH, Hirata M, Jasiulionis MG, Araujo RC, et al. Modification of epigenetic patterns in low birth weight children: importance of hypomethylation of the ACE gene promoter. PLoS One. 2014;9:e106138.","journal-title":"PLoS One"},{"key":"6733_CR91","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1161\/HYPERTENSIONAHA.115.06849","volume":"67","author":"S Ayyadevara","year":"2016","unstructured":"Ayyadevara S, Mercanti F, Wang X, Mackintosh SG, Tackett AJ, Prayaga SV, et al. Age- and hypertension-associated protein aggregates in mouse heart have similar proteomic profiles. Hypertension. 2016;67:1006\u201313.","journal-title":"Hypertension"},{"key":"6733_CR92","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/jcb.23091","volume":"112","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Jiang DS, Yan L, Cheng KJ, Bian ZY, Lin GS. HSP75 protects against cardiac hypertrophy and fibrosis. J Cell Biochem. 2011;112:1787\u201394.","journal-title":"J Cell Biochem"},{"key":"6733_CR93","unstructured":"Clinical pharmacogenetics implementation consortium. https:\/\/cpicpgx.org \/."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-017-6733-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-017-6733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-017-6733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T13:28:45Z","timestamp":1750771725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-017-6733-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["6733"],"URL":"https:\/\/doi.org\/10.1007\/s10557-017-6733-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]},"assertion":[{"value":"24 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Monte receives support from NIH 1 K23 GM110516 and NIH CTSI UL1 TR001082.Dr. Monte and Hania Flaten receive support from the American Medical Association Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent is not applicable in this review article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}